Your daily selection of the latest science news!
According to Latest Science News — ScienceDaily (This article and its images were originally posted on Latest Science News — ScienceDaily October 9, 2018 at 08:33AM.)
For the first time, scientists have performed prenatal gene editing to prevent a lethal metabolic disorder in laboratory animals, offering the potential to treat human congenital diseases before birth. Published today in Nature Medicine, research from Children’s Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania offers proof-of-concept for prenatal use of a sophisticated, low-toxicity tool that efficiently edits DNA building blocks in disease-causing genes.
Using both CRISPR-Cas9 and base editor 3 (BE3) gene-editing tools, the team reduced cholesterol levels in healthy mice treated in utero by targeting a gene that regulates those levels. They also used prenatal gene editing to improve liver function and prevent neonatal death in a subgroup of mice that had been engineered with a mutation causing the lethal liver disease hereditary tyrosinemia type 1 (HT1).
HT1 in humans usually appears during infancy, and it is often treatable with a medicine called nitisinone and a strict diet. However, when treatments fail, patients are at risk of liver failure or liver cancer. Prenatal treatment could open a door to disease prevention, for HT1 and potentially for other congenital disorders.
To see more posts like these; please subscribe to our newsletter. By entering a valid email, you’ll receive top trending reports delivered to your inbox.
This article and images were originally posted on [Latest Science News — ScienceDaily] October 9, 2018 at 08:33AM. Credit to the original author and Latest Science News — ScienceDaily | ESIST.T>G>S Recommended Articles Of The Day.